发明名称 |
Use of hemojuvelin fusion proteins to regulate hepcidin-mediated iron metabolism |
摘要 |
The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-² superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders. |
申请公布号 |
EP2335719(A1) |
申请公布日期 |
2011.06.22 |
申请号 |
EP20100196139 |
申请日期 |
2006.02.16 |
申请人 |
THE GENERAL HOSPITAL CORPORATION |
发明人 |
LIN, HERBERT Y;BABITT, JODIE;CHUNG, RAYMOND T;SAMAD, TAREK, A.;SCHNEYER, ALAN, L.;WOOLF, CLIFFORD |
分类号 |
A61K38/17;A61K39/395;A61K47/48;A61P3/02;A61P7/06 |
主分类号 |
A61K38/17 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|